These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17518508)

  • 21. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
    Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
    J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.
    Arlander E; Ekström G; Alm C; Carrillo JA; Bielenstein M; Böttiger Y; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Nov; 64(5):484-91. PubMed ID: 9834040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.
    Miceli JJ; Smith M; Robarge L; Morse T; Laurent A
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):71S-76S. PubMed ID: 10771458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.
    Harris RZ; Padhi D; Marbury TC; Noveck RJ; Salfi M; Sullivan JT
    Am J Kidney Dis; 2004 Dec; 44(6):1070-6. PubMed ID: 15558528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide.
    Böhmer GM; Drollmann A; Gleiter CH; Nave R
    Clin Pharmacokinet; 2008; 47(5):343-9. PubMed ID: 18399715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration.
    Seidegård J
    Clin Pharmacol Ther; 2000 Jul; 68(1):13-7. PubMed ID: 10945311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.
    Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
    Br J Clin Pharmacol; 2011 Apr; 71(4):522-7. PubMed ID: 21395644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.
    Kovarik JM; Huang HL; Slade A; Sfikas N; Chandler PA
    Br J Clin Pharmacol; 2009 Sep; 68(3):381-5. PubMed ID: 19740395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers.
    Ridtitid W; Ratsamemonthon K; Mahatthanatrakul W; Wongnawa M
    J Clin Pharm Ther; 2007 Dec; 32(6):585-93. PubMed ID: 18021336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
    Brynne N; Forslund C; Hallén B; Gustafsson LL; Bertilsson L
    Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic interaction between ketoconazole and SPP301 in healthy volunteers.
    Dieterle W; Mann J
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):326-30. PubMed ID: 16961161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
    Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
    Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
    Langdon G; Davis J; Layton G; Chong CL; Weissgerber G; Vourvahis M
    Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of irinotecan metabolism by ketoconazole.
    Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
    J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.
    van Giersbergen PL; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2002 Jun; 53(6):589-95. PubMed ID: 12047483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
    Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K
    Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
    Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
    Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
    Shin KH; Kim BH; Kim TE; Kim JW; Yi S; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Dec; 31(12):3009-20. PubMed ID: 20110038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.